Search results
Results From The WOW.Com Content Network
Infant respiratory distress syndrome (IRDS), also known as surfactant deficiency disorder (SDD), [2] and previously called hyaline membrane disease (HMD), is a syndrome in premature infants caused by developmental insufficiency of pulmonary surfactant production and structural immaturity in the lungs.
Bronchopulmonary dysplasia (BPD; part of the spectrum of chronic lung disease of infancy) is a chronic lung disease which affects premature infants. Premature (preterm) infants who require treatment with supplemental oxygen or require long-term oxygen are at a higher risk. [1]
It is the most common cause of respiratory distress in term neonates. [2] [3] It consists of a period of tachypnea (rapid breathing, higher than the normal range of 30–60 times per minute). Usually, this condition resolves over 24–72 hours. Treatment is supportive and may include supplemental oxygen and antibiotics.
Respiratory distress syndrome (RDS) - is a breathing problem that sometimes affects babies born six weeks or more before their due dates. Their lungs aren't developed enough to make surfactant, a liquid that coats the inside of the lungs and keeps them open so that the baby can breathe in air once he or she is born.
Antenatal steroids have also been shown to have definite beneficial effect in treating the condition of preterm premature rupture of membranes (PPROM). [8] Similar to its effects on preterm birth, research evidence suggests that the administration of antenatal steroids to patients with PPROM reduces risks of neonatal mortality, intraventricular hemorrhage and respiratory distress syndrome.
Over 50% of infants who are born preterm are estimated to be affected by apnea of prematurity. [2] Infants who are born weighing less than 1000g have close to a 100% risk of being affected by apnea of prematurity. Most premature infants are affected by 'central' apnea due to the developmental stage of their respiratory tract. [2]
The premature babies, who weigh less than 1.5 kg (3.3 pounds) each and in some cases only 700 or 800 grammes, should be in incubators where the temperature and humidity can be regulated according ...
Pulmonary surfactant is used as a medication to treat and prevent respiratory distress syndrome in newborn babies. [1] Prevention is generally done in babies born at a gestational age of less than 32 weeks. [1] It is given by the endotracheal tube. [1] Onset of effects is rapid. [2] A number of doses may be needed. [2]